Reporting Manager
Southpoint Master Fund, LP
Symbol
FENC
Shares outstanding
34,309,263 shares
Disclosed Ownership
2,744,741 shares
Ownership
8%
Form type
SCHEDULE 13G/A
Filing time
14 Jan 2026, 17:00:03 UTC
Date of event
31 Dec 2025

Sponsored

Quoteable Key Fact

"Southpoint Capital Advisors LP disclosed 8% ownership in Fennec Pharmaceuticals Inc. Common Shares, no par value (FENC) on 31 Dec 2025."

Quick Takeaways

  • Southpoint Capital Advisors LP filed SCHEDULE 13G/A for Fennec Pharmaceuticals Inc. Common Shares, no par value (FENC).
  • Disclosed ownership: 8%.
  • Date of event: 31 Dec 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Jan 2026, 17:00.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Southpoint Master Fund, LP 8% 2,744,741 0 2,744,741 /s/ John S. Clark II By Southpoint GP, LP, its General Partner, by Southpoint GP LLC, its General Partner, by John S. Clark II, Managing Member
Southpoint Capital Advisors LP 8% 2,744,741 0 2,744,741 /s/ John S. Clark II By Southpoint Capital Advisors LLC, its General Partner, by John S. Clark II, Managing Member
Southpoint Capital Advisors LLC 8% 2,744,741 0 2,744,741 /s/ John S. Clark II John S. Clark II, Managing Member
Southpoint GP, LP 8% 2,744,741 0 2,744,741 /s/ John S. Clark II John S. Clark II, Managing Member
Southpoint GP, LLC 8% 2,744,741 0 2,744,741 /s/ John S. Clark II John S. Clark II, Managing Member
John S. Clark II 8% 2,744,741 0 2,744,741 /s/ John S. Clark II John S. Clark II, individually